VistaGen Therapeutics Inc (VTGN)

[Fress]

Invest in the dip...... this stock is under accumulation and I could see it breaking out higher.

Adding huge on the dip. Stock traded at $3.18 recently. Primed to double in price soon!

Get your shares and hold them. Lock them up GTC sky high.

Phase 3 is where the rubber meets the road.


THERE IS A TIGER RAGING INSIDE HER CAGE, & SHE'S GOING TO BREAK HER CHAINS AND SCREAM THROUGH THE JUNGLE, THIS WILL CREATE THUNDER BEYONG WHAT WE HAVE EVER SEEN.



VistaGen just initiated with Buy at Jefferies on 'upside potential' for anxiety drug $6.00-8.00 Target this year.

Anticipated Study Catalysts:
1. Successful Phase 2 program completed; preparing for pivotal Phase 3 clinical development FAST TRACKED
2. AffaMed Therapeutics has exclusive rights to develop and commercialize in certain markets in Asia
3. Preparing for Phase 2A program
4. Assessing for potential Phase 2A program
5. Successful Phase 2A program completed; preparing for Phase 2B program
6. Assessing for Phase 1B to support potential Phase 2A


VTGN Pipeline:
https://www.vistagen.com/pipeline

VTGN Biz presentation:
https://d1io3yog0oux5.cloudfront.net/_78f83b9b022497768da4a497c4d9e5
b2/vistagen/db/241/816/pdf/VistaGen+Corporate+Presentation+Website+2020_11_16+250pm+PT.pdf

VTGN Twitter:
https://twitter.com/VistaGen?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

Anxiety depression peers:
$CMPS 1.7 billion market cap early clinical trials. 190 million cash
$MMEDF 1.1 billion market cap.
$SAGE 5 Billion market cap bought out a few weeks ago for deperession anxiety pipeline.
$VTGN 315 million market cap Phase 3 ready. (nasdaq)
115 million in cash


$VTGN